MARKET

AGIO

AGIO

Agios
NASDAQ

Real-time Quotes | Nasdaq Last Sale

44.08
-0.17
-0.38%
After Hours: 44.08 0 0.00% 16:07 12/11 EST
OPEN
44.32
PREV CLOSE
44.25
HIGH
44.97
LOW
43.39
VOLUME
772.95K
TURNOVER
--
52 WEEK HIGH
68.94
52 WEEK LOW
28.36
MARKET CAP
2.96B
P/E (TTM)
-6.4386
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AGIO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

AGIO News

  • Agios Pharmaceuticals (AGIO) Presents At 2019 ASH Annual Meeting - Slideshow
  • Seeking Alpha - Article.17h ago
  • Here Are The Winners From The Year's Biggest Hematology Meeting
  • Investor's Business Daily.2d ago
  • Agios Pharma Offers Updated Data From Mitapivat From Extension Phase Of DRIVE PK Study In Patients With Pyruvate Kinase Deficiency
  • Benzinga.2d ago
  • Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency
  • GlobeNewswire.2d ago

More

Industry

Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About AGIO

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
More

Webull offers Agios Pharmaceuticals Inc (AGIO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.